- Home
- IRON vs TLRY Comparison
IRON vs TLRY Comparison
Compare IRON & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- TLRY
- Stock Information
- Founded
- IRON 2017
- TLRY N/A
- Country
- IRON United States
- TLRY Canada
- Employees
- IRON N/A
- TLRY N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- TLRY Medicinal Chemicals and Botanical Products
- Sector
- IRON Health Care
- TLRY Health Care
- Exchange
- IRON Nasdaq
- TLRY Nasdaq
- Market Cap
- IRON 2.1B
- TLRY 1.8B
- IPO Year
- IRON N/A
- TLRY 2018
- Fundamental
- Price
- IRON $67.78
- TLRY $1.62
- Analyst Decision
- IRON Strong Buy
- TLRY Buy
- Analyst Count
- IRON 10
- TLRY 4
- Target Price
- IRON $97.80
- TLRY $1.58
- AVG Volume (30 Days)
- IRON 380.9K
- TLRY 73.9M
- Earning Date
- IRON 11-11-2025
- TLRY 10-09-2025
- Dividend Yield
- IRON N/A
- TLRY N/A
- EPS Growth
- IRON N/A
- TLRY N/A
- EPS
- IRON N/A
- TLRY N/A
- Revenue
- IRON N/A
- TLRY $821,309,000.00
- Revenue This Year
- IRON N/A
- TLRY $6.66
- Revenue Next Year
- IRON N/A
- TLRY $4.75
- P/E Ratio
- IRON N/A
- TLRY N/A
- Revenue Growth
- IRON N/A
- TLRY 4.10
- 52 Week Low
- IRON $30.82
- TLRY $0.35
- 52 Week High
- IRON $68.79
- TLRY $1.88
- Technical
- Relative Strength Index (RSI)
- IRON 69.97
- TLRY 63.07
- Support Level
- IRON $65.26
- TLRY $1.14
- Resistance Level
- IRON $68.79
- TLRY $1.88
- Average True Range (ATR)
- IRON 2.67
- TLRY 0.14
- MACD
- IRON 0.53
- TLRY 0.04
- Stochastic Oscillator
- IRON 88.97
- TLRY 64.86
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mostly from alcohol.